A meeting to determine if a project is a go or no go seems to rely heavily on the risk management. It seems like a good idea to have multiple departments involved in this process to fully identify the risks associated with the project. Risk in pharma is certainly different than risk in a medical device company. Risk in pharma could be activating different cascades or signals that are not the intended target. Risk in a medical device could lead to failure. For risk to be identified, once would have to understand the project and know what the intended use and scope is. Having that understanding would help to go a long way in these meetings.